Evgen Pharma PLC Collaboration with Università Sapienza di Roma
25 Mayo 2022 - 02:31AM
RNS Non-Regulatory
TIDMEVG
Evgen Pharma PLC
25 May 2022
Evgen Pharma plc
("Evgen" or the "Company")
Evgen announces collaboration with Università Sapienza di
Roma
to evaluate radiosensitisation effects of lead asset, SFX-01
Alderley Park, UK - 25 May 2022: Evgen Pharma plc (AIM: EVG), a
clinical stage drug development company developing
sulforaphane-based medicines for the treatment of cancer and other
indications, announces a collaboration with Prof. Francesco
Marampon, of Università Sapienza di Roma (La Sapienza) to
investigate potential radiosensitisation effects of the Company's
lead asset, SFX-01.
The aim of radiosensitisation is to make tumour cells more
sensitive to radiation therapy and through this, to improve
effectiveness.
SFX-01 is a patented composition of synthetic sulforaphane and
alpha-cyclodextrin. Previous studies of the compound have shown an
increase in sensitivity of cancer cells to radiotherapy in its
presence. This was observed in in vitro and in vivo models of
glioblastoma. Results of the study were published in a peer
reviewed journal, Pharmaceuticals, in 2021 ( Colapietro et al 2021
).
The collaboration with La Sapienza seeks to evaluate the
radiosensitisation effects of SFX-01 in a different tumour type and
to provide further insights into its mechanism of action. In vitro
experiments will investigate the ability of SFX-01 to increase the
sensitivity of cells to radiotherapy and allow the use of lower
radiation doses. Factors that will be investigated include the
inhibitory effects of SFX-01 on cell metabolism, focusing on
proliferation, cell cycle distribution and induction of death.
Dr Huw Jones, Evgen CEO, commented: "This new collaboration with
Prof. Marampon's group aims to gain further insights into the
striking effects seen with SFX-01 in combination with radiotherapy.
If radiosensitisation is a feature of SFX-01, this could be an
important step forward in the treatment of cancers requiring
radiotherapy. This will be our 14(th) academic collaboration and is
part of our ongoing strategy to add to the broad dataset already in
place of SFX-01's mode of action and safety features."
Prof. Francesco Marampon, of Università Sapienza di Roma, Lead
Investigator, commented: "Based on previous promising data with
SFX-01, we will be looking to understand the effects of SFX-01 as a
potential radiosensitiser for cancer patients. The ultimate aim is
to improve the impact of radiotherapy and facilitate recovery."
Evgen's core technology is Sulforadex(R), a method for
synthesising and stabilising the naturally occurring compound
sulforaphane and novel proprietary analogues based on sulforaphane.
Sulforaphanes have shown potential benefits in oncology and
inflammation by binding with several targets of particular
relevance in cancer.
-Ends-
Enquiries:
Evgen Pharma plc Tel: +44 1625 466591
Dr Huw Jones, CEO
Richard Moulson, CFO
FinnCap (Nominated Advisor and Broker) Tel: +44 20 7220 0500
Geoff Nash / Teddy Whiley (Corporate Finance)
Alice Lane/Nigel Birks (ECM)
Instinctif Partners Tel: +44 207 457 2020
Melanie Toyne-Sewell / Rozi Morris / Agnes Stephens / Jonjo Cordey Evgen@Instinctif.com
Notes to Editors
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company
developing sulforaphane based medicines for the treatment of
multiple diseases. The Company's core technology is Sulforadex(R),
a method for synthesising and stabilising the naturally occurring
compound sulforaphane and novel proprietary analogues based on
sulforaphane.
The Company's lead asset, SFX-01, is a patented composition of
synthetic sulforaphane and alpha-cyclodextrin and has undergone
clinical trials for oestrogen-positive (ER+) metastatic breast
cancer. It will be entering the clinic in glioma/glioblastoma later
in 2022. In September 2021 the FDA granted Orphan Drug status to
SFX-01 in malignant glioma.
The Company also has a wide number of collaborations with
leading academic centres in the UK, Europe and AsiaPac as part of
the continuing strategy to build the data set of safety and
efficacy around the compound. With respect to non-core areas, Evgen
signed an outlicensing deal with JuvLife, the dietary products and
functional foods division of Juvenescence Ltd, for the development
of a naturally-sourced sulforaphane nutritional health supplement,
stabilised using Evgen's Sulforadex(R) technology.
The Company commenced operations in January 2008 and has its
headquarters and registered office at Alderley Park, Cheshire. It
joined the AIM market of the London Stock Exchange in October 2015
and trades under the ticker symbol EVG.
For further information, please visit: www.evgen.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRASEUFALEESEEI
(END) Dow Jones Newswires
May 25, 2022 03:31 ET (07:31 GMT)
Evgen Pharma (LSE:EVG)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Evgen Pharma (LSE:EVG)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024